US 12,357,708 · Application 18/820,804 · Granted Jul 15, 2025

US 12,357,708

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

Estimated expiration

October 3, 2031

5y 4d remaining

Confidence: high

Earliest effective filing

Oct 3, 2011

+ 20 years

Oct 3, 2031

PTA +0d

Oct 3, 2031

TD cap (US 10,064,959)

Oct 3, 2031

Final

Oct 3, 2031

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date: August 30, 2024
Earliest effective filing: October 3, 2011
Issue date: July 15, 2025
PTA: 0 days
Base expiry (before PTA): October 3, 2031

October 3, 2011 + 20 years = October 3, 2031

Continuation of application 18/045,805, filed Oct 11, 2022, issued as US 12,496,358
Continuation of application 16/047,574, filed Jul 27, 2018
Continuation of application 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of application 13/481,127, filed May 25, 2012
Continuation of application 13/251,840, filed Oct 3, 2011
Continuation of application 13/251,840, filed Oct 3, 2011
Continuation of application 13/481,127, filed May 25, 2012
Continuation of application 13/251,840, filed Oct 3, 2011
Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of application 13/481,127, filed May 25, 2012
Continuation of application 13/251,840, filed Oct 3, 2011
Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of application 13/481,127, filed May 25, 2012
Continuation of application 13/251,840, filed Oct 3, 2011
Continuation of application 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of application 13/481,127, filed May 25, 2012
Continuation of application 13/251,840, filed Oct 3, 2011
Continuation of application 16/047,574, filed Jul 27, 2018
Continuation of application 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of application 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of application 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of application 13/481,127, filed May 25, 2012
Continuation of application 13/251,840, filed Oct 3, 2011
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term
PRO61/404,413 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to October 3, 2031 (earliest expiring referenced patent: US 10,064,959)

US 9,334,328· Application 13/739,212Capping patent
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
Filing date
Jan 11, 2013
Earliest effective filing
Oct 3, 2011
Issue date
May 10, 2016
PTA
+76 days
Calculated expiration
Dec 18, 2031
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/251,840, filed Oct 3, 2011
Oct 3, 2011 + 20y + 76d PTA = Dec 18, 2031
US 10,064,959· Application 15/493,829Capping patent
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
Filing date
Apr 21, 2017
Earliest effective filing
Oct 3, 2011
Issue date
Sep 4, 2018
PTA
0 days
Calculated expiration
Oct 3, 2031
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Oct 3, 2011 + 20y = Oct 3, 2031
US 12,357,708· Application 18/820,804(from application 18/820,804)
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
Filing date
Aug 30, 2024
Earliest effective filing
Oct 3, 2011
Issue date
Jul 15, 2025
PTA
0 days
Calculated expiration
Oct 3, 2031
Continuation of 18/045,805, filed Oct 11, 2022, issued as US 12,496,358
Continuation of 16/047,574, filed Jul 27, 2018
Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 16/047,574, filed Jul 27, 2018
Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Oct 3, 2011 + 20y = Oct 3, 2031
US 12,496,358· Application 18/045,805(from application 18/045,805)
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
Filing date
Oct 11, 2022
Earliest effective filing
Oct 3, 2011
Issue date
Dec 16, 2025
PTA
+399 days
Calculated expiration
Nov 5, 2032
Continuation of 16/047,574, filed Jul 27, 2018
Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Continuation of 15/493,829, filed Apr 21, 2017, issued as US 10,064,959
Divisional of 15/143,364, filed Apr 29, 2016, issued as US 9,657,295
Continuation of 13/739,212, filed Jan 11, 2013, issued as US 9,334,328
Continuation of 13/481,127, filed May 25, 2012
Continuation of 13/251,840, filed Oct 3, 2011
Oct 3, 2011 + 20y + 399d PTA = Nov 5, 2032

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

The prosecution record for your AI

Application 18/820,804 · US 12,357,708

You have the date. Your AI can have the file.

PatentReply compiles the prosecution history behind US 12,357,708: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new public application a month is free. The first compile takes a few minutes.

Connect PatentReply See the evidence

Strategy and filing changes require your approval.

Look up another patentWho owns this patent?

Permanent link

www.patentreply.ai/tools/patent-expiration/US12357708

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.

Estimated expiration

Calculation details

Base term

Continuity chain(36 links)

Terminal disclaimers

Referenced patents(4)

You have the date. Your AI can have the file.